

ABSTRACT

The present invention provides a recombinant human *N*-acetylgalactosamine-4-sulfatase (rhASB) and biologically active mutants, fragments and analogs thereof as well as
5 pharmaceutical formulations comprising recombinant human *N*-acetylgalactosamine-4-sulfatase (rhASB). The invention also provides methods for treating diseases caused all or in part by deficiencies in human *N*-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant enzyme.